organization · Reporting owner
NORWEST VENTURE PARTNERS XI, LP
Disclosed activity across 3 companies
Sign in to followReported relationships
Latest disclosed role at each company.
No relationships currently tracked through insider filings.
Disclosed balances
About these balances
Latest available filing per company, not a reconstructed current portfolio. Matching sequences show the last reported balance with all source rows expandable; grouping alone does not establish account ownership. Do not add unresolved positions together. Filings may omit unchanged positions, and amendments may correct only part of an older disclosure. Jointly reported shares are not necessarily this owner's personal holdings.
No balances currently tracked through insider filings.
Past disclosures · reporting ended (3)
No longer tracked through insider filings. These historical balances do not imply present ownership or a zero position.
Apigee Corp
Report date October 25, 2016 · Filed October 28, 2016 · Amendment
Jointly reported with Norwest Venture Partners IX, LP, Crowe Jeffrey, Howard Matthew D., NORWEST VENTURE PARTNERS VIII LP
Section 16 reporting ended · disclosed 2016-10-28. Current position is not established by this disclosure.
Amendment: balances below belong to this corrected disclosure, not necessarily a complete replacement of earlier positions.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | IndirectBy Limited Partnership | 102,465 |
Reported balance
After 2016-10-25 transaction · row 1
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 1 · 2016-10-25 · Other · Disposed 4,874,426 · Balance 102,465 F1: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners IX, LP ("NVP IX") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP IX, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F2: The NVP IX distribution resulted in a change in the form of beneficial ownership so that following the distribution (i) 68,317 shares were beneficially owned by the Howard 2001 Revocable Trust, of which Mr. Howard is a trustee, and (ii) 34,148 shares were beneficially owned by the Crowe Family Trust, 12/22/88, of which Mr. Crowe is a trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Limited Partnership | 1,866 |
Reported balance
After 2016-10-25 transaction · row 2
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 2 · 2016-10-25 · Other · Disposed 871,695 · Balance 1,866 F3: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners VIII, LP ("NVP VIII") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP VIII, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F4: The NVP VIII distribution resulted in a change in the form of beneficial ownership so that following the distribution 1,866 shares were beneficially owned by the Howard 2001 Revocable Trust, of which Mr. Howard is a trustee. |
| Common StockSEC Table I · non-derivative | IndirectBy Limited Partnership | 0 |
Reported balance
After 2016-10-25 transaction · row 3
Amendment: may correct only part of an earlier disclosure.
1 source rowRow 3 · 2016-10-25 · Other · Disposed 472,557 · Balance 0 F5: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F6: The securities shown on Line 3 of Table 1 represent securities held of record by NVP XI. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Messers. Crowe and Howard may be deemed to share voting and dispositive power over the shares held by NVP XI. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners IX, LP ("NVP IX") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP IX, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
F2: The NVP IX distribution resulted in a change in the form of beneficial ownership so that following the distribution (i) 68,317 shares were beneficially owned by the Howard 2001 Revocable Trust, of which Mr. Howard is a trustee, and (ii) 34,148 shares were beneficially owned by the Crowe Family Trust, 12/22/88, of which Mr. Crowe is a trustee.
F3: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners VIII, LP ("NVP VIII") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP VIII, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
F4: The NVP VIII distribution resulted in a change in the form of beneficial ownership so that following the distribution 1,866 shares were beneficially owned by the Howard 2001 Revocable Trust, of which Mr. Howard is a trustee.
F5: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
F6: The securities shown on Line 3 of Table 1 represent securities held of record by NVP XI. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Messers. Crowe and Howard may be deemed to share voting and dispositive power over the shares held by NVP XI. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
Health Catalyst, Inc.
Report date July 15, 2020 · Filed July 17, 2020
Jointly reported with Norwest Venture Partners XII, LP, Crowe Jeffrey, Kossow Jon Erik
Section 16 reporting ended · disclosed 2020-07-17. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 1,752,214 |
Reported balance
After 2020-07-15 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2020-07-15 · Other · Disposed 599,939 · Balance 1,752,214 F1: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited partners. F2: The NVP XI distribution resulted in a change in the form of beneficial ownership so that following the distribution 123 shares were beneficially owned by Kossow Family Trust, of which Mr. Kossow is a Trustee. The remaining 1,752,091 shares are held of record by NVP XI. Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. |
| Common StockSEC Table I · non-derivative | IndirectBy Limited Partnership | 1,752,090 |
Reported balance
After 2020-07-15 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2020-07-15 · Other · Disposed 600,000 · Balance 1,752,090 F3: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited partners. F4: The securities shown on Line 2 of Table I represent securities held of record by NVP XII. Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited partners.
F2: The NVP XI distribution resulted in a change in the form of beneficial ownership so that following the distribution 123 shares were beneficially owned by Kossow Family Trust, of which Mr. Kossow is a Trustee. The remaining 1,752,091 shares are held of record by NVP XI. Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
F3: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited partners.
F4: The securities shown on Line 2 of Table I represent securities held of record by NVP XII. Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
iRhythm Holdings, Inc.
Report date May 08, 2017 · Filed May 10, 2017
Jointly reported with Crowe Jeffrey, Howard Matthew D., Norwest Venture Partners XII, LP, HAQUE PROMOD
Section 16 reporting ended · disclosed 2017-05-10. Current position is not established by this disclosure.
| Security / award | Ownership account | Disclosed shares / units | Disclosure context |
|---|---|---|---|
| Common StockSEC Table I · non-derivative | Direct | 284,747 |
Reported balance
After 2017-05-08 transaction · row 1
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 1 · 2017-05-08 · Other · Disposed 900,000 · Balance 284,747 F1: The securities shown on Line 1 of Table I represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). By virtue of their positions as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messrs. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F2: Shares were disposed via a pro rata in-kind distribution of Issuer's common stock from NVP XI to its limited and general partners. |
| Common StockSEC Table I · non-derivative | IndirectBy Limited Partnership | 284,747 |
Reported balance
After 2017-05-08 transaction · row 2
Joint disclosure: continuity of the reported position is unresolved; see ownership footnotes.
1 source rowRow 2 · 2017-05-08 · Other · Disposed 900,000 · Balance 284,747 F3: Shares were disposed via a pro rata in-kind distribution of Issuer's common stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited and general partners. F4: The securities shown on Line 2 of Table I represent securities held of record by NVP XII. By virtue of their positions as co-Chief Executive Officers of NVP Associates, the managing member of the general partner of NVP XII, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messers. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. |
Filing footnotes · ownership attribution and instrument terms
F1: The securities shown on Line 1 of Table I represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). By virtue of their positions as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messrs. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
F2: Shares were disposed via a pro rata in-kind distribution of Issuer's common stock from NVP XI to its limited and general partners.
F3: Shares were disposed via a pro rata in-kind distribution of Issuer's common stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited and general partners.
F4: The securities shown on Line 2 of Table I represent securities held of record by NVP XII. By virtue of their positions as co-Chief Executive Officers of NVP Associates, the managing member of the general partner of NVP XII, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messers. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein.
Transaction history
JSON APIPurchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Company | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| July 15, 2020 Filed Jul 17, 2020 18:00 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | OtherCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042940 · doc4.xml · nonDerivative · entry 2 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 1,752,090 F3 · kind: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited partners. F3 · price: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited partners. F4 · ownership.nature: The securities shown on Line 2 of Table I represent securities held of record by NVP XII. Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 15, 2020 Filed Jul 17, 2020 18:00 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | OtherCommon Stock | 599,939 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-042940 · doc4.xml · nonDerivative · entry 1 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,752,214 F1 · kind: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited partners. F1 · price: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited partners. F2 · balance_after: The NVP XI distribution resulted in a change in the form of beneficial ownership so that following the distribution 123 shares were beneficially owned by Kossow Family Trust, of which Mr. Kossow is a Trustee. The remaining 1,752,091 shares are held of record by NVP XI. Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 17:30 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | OtherCommon Stock | 600,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004714 · doc4.xml · nonDerivative · entry 2 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 2,352,090 F3 · kind: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited partners. F3 · price: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited partners. F4 · ownership.nature: The securities shown on Line 2 of Table I represent securities held of record by NVP XII. Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| January 21, 2020 Filed Jan 23, 2020 17:30 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | OtherCommon Stock | 599,938 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-20-004714 · doc4.xml · nonDerivative · entry 1 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,352,153 F1 · kind: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited partners. F1 · price: Shares were disposed of via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited partners. F2 · balance_after: The NVP XI distribution resulted in a change in the form of beneficial ownership so that following the distribution 62 shares were beneficially owned by Kossow Family Trust, of which Mr. Kossow is a Trustee. The remaining 2,352,091 shares are held of record by NVP XI. Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries F Convertible Preferred Stock · Derivative | 35,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 12 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 Underlying: Common Stock · 35,919 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F6 · derivative.exercise_price: The Series F Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F6 · derivative.exercise_date: The Series F Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F6 · derivative.expiration_date: The Series F Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F7 · ownership.nature: The securities shown on Line 2 of Table I and Lines 6 through 10 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries E Convertible Preferred Stock · Derivative | 424,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 11 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 Underlying: Common Stock · 424,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F5 · derivative.exercise_date: The Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F5 · derivative.expiration_date: The Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F7 · ownership.nature: The securities shown on Line 2 of Table I and Lines 6 through 10 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries D Convertible Preferred Stock · Derivative | 471,831 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 10 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 Underlying: Common Stock · 471,831 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F4 · derivative.exercise_date: The Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F4 · derivative.expiration_date: The Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F7 · ownership.nature: The securities shown on Line 2 of Table I and Lines 6 through 10 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries C Convertible Preferred Stock · Derivative | 577,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 9 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 Underlying: Common Stock · 577,045 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · derivative.exercise_price: The Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F3 · derivative.exercise_date: The Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F3 · derivative.expiration_date: The Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F7 · ownership.nature: The securities shown on Line 2 of Table I and Lines 6 through 10 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,442,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 8 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 Underlying: Common Stock · 1,442,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · derivative.exercise_price: The Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2 · derivative.exercise_date: The Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2 · derivative.expiration_date: The Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F7 · ownership.nature: The securities shown on Line 2 of Table I and Lines 6 through 10 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries F Convertible Preferred Stock · Derivative | 35,919 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 7 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 35,919 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities shown on Line 1 of Table I and Lines 1 through 5 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F6 · derivative.exercise_price: The Series F Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F6 · derivative.exercise_date: The Series F Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F6 · derivative.expiration_date: The Series F Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries E Convertible Preferred Stock · Derivative | 424,568 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 6 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 424,568 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities shown on Line 1 of Table I and Lines 1 through 5 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F5 · derivative.exercise_price: The Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F5 · derivative.exercise_date: The Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F5 · derivative.expiration_date: The Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries D Convertible Preferred Stock · Derivative | 471,832 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 5 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 471,832 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities shown on Line 1 of Table I and Lines 1 through 5 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F4 · derivative.exercise_price: The Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F4 · derivative.exercise_date: The Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F4 · derivative.expiration_date: The Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries C Convertible Preferred Stock · Derivative | 577,045 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 4 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 577,045 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities shown on Line 1 of Table I and Lines 1 through 5 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F3 · derivative.exercise_price: The Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F3 · derivative.exercise_date: The Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F3 · derivative.expiration_date: The Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionSeries B Convertible Preferred Stock · Derivative | 1,442,727 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · derivative · entry 3 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 1,442,727 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities shown on Line 1 of Table I and Lines 1 through 5 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F2 · derivative.exercise_price: The Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2 · derivative.exercise_date: The Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F2 · derivative.expiration_date: The Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionCommon Stock | 2,952,090 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · nonDerivative · entry 2 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 2,952,090 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · price: The Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F3 · price: The Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F4 · price: The Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F5 · price: The Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F6 · price: The Series F Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F7 · ownership.nature: The securities shown on Line 2 of Table I and Lines 6 through 10 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). Genesis VC Partners XII, LLC ("Genesis XII") is the general partner of NVP XII and may be deemed to have sole voting and dispositive power over the shares held by NVP XII. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XII, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| July 29, 2019 Filed Jul 29, 2019 21:02 UTC | Health Catalyst, Inc. HCAT · Entity 1565 | ConversionCommon Stock | 2,952,091 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-19-043590 · doc4.xml · nonDerivative · entry 1 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Kossow Jon Erik · CIK 0001726084 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 2,952,091 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities shown on Line 1 of Table I and Lines 1 through 5 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). Genesis VC Partners XI, LLC ("Genesis XI") is the general partner of NVP XI and may be deemed to have sole voting and dispositive power over the shares held by NVP XI. NVP Associates, LLC ("NVP Associates"), the managing member of Genesis XI, and Jeffrey Crowe and Jon E. Kossow, as Co-Chief Executive Officers of NVP Associates, may be deemed to share voting and dispositive power with respect to such securities. Such entities, Crowe and Kossow disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F2 · price: The Series B Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F3 · price: The Series C Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F4 · price: The Series D Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F5 · price: The Series E Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. F6 · price: The Series F Convertible Preferred Stock automatically converted into Common Stock on a 1:1 basis immediately prior to the completion of the Issuer's initial public offering of Common Stock and has no expiration date. Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:47 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | OtherCommon Stock | 900,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-031386 · doc4.xml · nonDerivative · entry 2 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner HAQUE PROMOD · CIK 0001089744 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 284,747 F3 · kind: Shares were disposed via a pro rata in-kind distribution of Issuer's common stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited and general partners. F3 · price: Shares were disposed via a pro rata in-kind distribution of Issuer's common stock from Norwest Venture Partners XII, LP ("NVP XII") to its limited and general partners. F4 · ownership.nature: The securities shown on Line 2 of Table I represent securities held of record by NVP XII. By virtue of their positions as co-Chief Executive Officers of NVP Associates, the managing member of the general partner of NVP XII, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messers. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| May 08, 2017 Filed May 10, 2017 17:47 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | OtherCommon Stock | 900,000 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-17-031386 · doc4.xml · nonDerivative · entry 1 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner HAQUE PROMOD · CIK 0001089744 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 284,747 F1 · security: The securities shown on Line 1 of Table I represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). By virtue of their positions as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messrs. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F2 · kind: Shares were disposed via a pro rata in-kind distribution of Issuer's common stock from NVP XI to its limited and general partners. F2 · price: Shares were disposed via a pro rata in-kind distribution of Issuer's common stock from NVP XI to its limited and general partners. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 19:54 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | ConversionSeries E Convertible Preferred Stock · Derivative | 397,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146911 · doc4.xml · derivative · entry 6 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner HAQUE PROMOD · CIK 0001089744 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 Underlying: Common Stock · 397,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F5 · derivative.exercise_price: The Series E Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F5 · derivative.exercise_date: The Series E Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F5 · derivative.expiration_date: The Series E Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F6 · ownership.nature: The securities shown on Line 2 of Table I and Lines 3 and 4 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). By virtue of their positions as co-Chief Executive Officers of NVP Associates, LLC("NVP Associates"), the managing member of the general partner of NVP XII, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messers. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 19:54 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | ConversionSeries D Convertible Preferred Stock · Derivative | 786,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146911 · doc4.xml · derivative · entry 5 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner HAQUE PROMOD · CIK 0001089744 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 Underlying: Common Stock · 786,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · derivative.exercise_price: The Series D Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F4 · derivative.exercise_date: The Series D Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F4 · derivative.expiration_date: The Series D Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F6 · ownership.nature: The securities shown on Line 2 of Table I and Lines 3 and 4 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). By virtue of their positions as co-Chief Executive Officers of NVP Associates, LLC("NVP Associates"), the managing member of the general partner of NVP XII, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messers. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 19:54 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | ConversionSeries E Convertible Preferred Stock · Derivative | 397,883 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146911 · doc4.xml · derivative · entry 4 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner HAQUE PROMOD · CIK 0001089744 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 397,883 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities shown on Line 1 of Table I and Lines 1 and 2 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). By virtue of their positions as co-Chief Executive Officers of NVP Associates, LLC("NVP Associates"), the managing member of the general partner of NVP XI, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messrs. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F3 · derivative.exercise_price: The Series E Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F3 · derivative.exercise_date: The Series E Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F3 · derivative.expiration_date: The Series E Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 19:54 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | ConversionSeries D Convertible Preferred Stock · Derivative | 786,864 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-146911 · doc4.xml · derivative · entry 3 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner HAQUE PROMOD · CIK 0001089744 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Stock · 786,864 shares Expires not disclosed Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities shown on Line 1 of Table I and Lines 1 and 2 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). By virtue of their positions as co-Chief Executive Officers of NVP Associates, LLC("NVP Associates"), the managing member of the general partner of NVP XI, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messrs. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F2 · derivative.exercise_price: The Series D Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F2 · derivative.exercise_date: The Series D Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F2 · derivative.expiration_date: The Series D Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 19:54 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | ConversionCommon Stock | 1,184,747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-146911 · doc4.xml · nonDerivative · entry 2 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner HAQUE PROMOD · CIK 0001089744 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 1,184,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · price: The Series D Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F5 · price: The Series E Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F6 · ownership.nature: The securities shown on Line 2 of Table I and Lines 3 and 4 of Table II represent securities held of record by Norwest Venture Partners XII, LP ("NVP XII"). By virtue of their positions as co-Chief Executive Officers of NVP Associates, LLC("NVP Associates"), the managing member of the general partner of NVP XII, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messers. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| October 25, 2016 Filed Oct 25, 2016 19:54 UTC | iRhythm Holdings, Inc. IRTC · Entity 1499 | ConversionCommon Stock | 1,184,747 | Not disclosed | Not disclosed |
DisclosureSEC source: 0001209191-16-146911 · doc4.xml · nonDerivative · entry 1 Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner Norwest Venture Partners XII, LP · CIK 0001614660 · 10% owner HAQUE PROMOD · CIK 0001089744 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 1,184,747 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: The securities shown on Line 1 of Table I and Lines 1 and 2 of Table II represent securities held of record by Norwest Venture Partners XI, LP ("NVP XI"). By virtue of their positions as co-Chief Executive Officers of NVP Associates, LLC("NVP Associates"), the managing member of the general partner of NVP XI, Promod Haque, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power with respect to such securities. Messrs. Haque, Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F2 · price: The Series D Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. F3 · price: The Series E Convertible Preferred Stock automatically converted into common stock on a one for one basis immediately prior to the completion of the Issuer's initial public offering of common stock and has no expiration date. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 18:47 UTC | Apigee Corp APIC · Entity 181062 | OtherCommon Stock | 873,561 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147200 · doc4.xml · nonDerivative · entry 2 Norwest Venture Partners IX, LP · CIK 0001309124 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner NORWEST VENTURE PARTNERS VIII LP · CIK 0001176230 · 10% owner Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 F3 · kind: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners VIII, LP ("NVP VIII") to its limited and general partners. F3 · price: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners VIII, LP ("NVP VIII") to its limited and general partners. F4 · ownership.nature: The securities shown on Line 2 of Table 1 represent securities held of record by NVP VIII. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP VIII, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP VIII. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| October 25, 2016 Filed Oct 27, 2016 18:47 UTC | Apigee Corp APIC · Entity 181062 | OtherCommon Stock | 4,976,891 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147200 · doc4.xml · nonDerivative · entry 1 Norwest Venture Partners IX, LP · CIK 0001309124 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner NORWEST VENTURE PARTNERS VIII LP · CIK 0001176230 · 10% owner Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 F1 · kind: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners IX, LP ("NVP IX") to its limited and general partners. F1 · price: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners IX, LP ("NVP IX") to its limited and general partners. F2 · ownership.direct: The securities shown on Line 1 of Table 1 represent securities held of record by NVP IX. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP IX, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| October 25, 2016 Filed Oct 28, 2016 17:11 UTC Amendment | Apigee Corp APIC · Entity 181062 | OtherCommon Stock | 472,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147329 · doc4a.xml · nonDerivative · entry 3 Norwest Venture Partners IX, LP · CIK 0001309124 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner NORWEST VENTURE PARTNERS VIII LP · CIK 0001176230 · 10% owner Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 F5 · kind: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F5 · price: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F6 · ownership.nature: The securities shown on Line 3 of Table 1 represent securities held of record by NVP XI. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Messers. Crowe and Howard may be deemed to share voting and dispositive power over the shares held by NVP XI. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
| October 25, 2016 Filed Oct 28, 2016 17:11 UTC Amendment | Apigee Corp APIC · Entity 181062 | OtherCommon Stock | 871,695 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147329 · doc4a.xml · nonDerivative · entry 2 Norwest Venture Partners IX, LP · CIK 0001309124 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner NORWEST VENTURE PARTNERS VIII LP · CIK 0001176230 · 10% owner Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 1,866 F3 · kind: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners VIII, LP ("NVP VIII") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP VIII, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F3 · price: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners VIII, LP ("NVP VIII") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP VIII, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F4 · balance_after: The NVP VIII distribution resulted in a change in the form of beneficial ownership so that following the distribution 1,866 shares were beneficially owned by the Howard 2001 Revocable Trust, of which Mr. Howard is a trustee. F4 · ownership.nature: The NVP VIII distribution resulted in a change in the form of beneficial ownership so that following the distribution 1,866 shares were beneficially owned by the Howard 2001 Revocable Trust, of which Mr. Howard is a trustee. Read SEC document |
| October 25, 2016 Filed Oct 28, 2016 17:11 UTC Amendment | Apigee Corp APIC · Entity 181062 | OtherCommon Stock | 4,874,426 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147329 · doc4a.xml · nonDerivative · entry 1 Norwest Venture Partners IX, LP · CIK 0001309124 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner NORWEST VENTURE PARTNERS VIII LP · CIK 0001176230 · 10% owner Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 102,465 F1 · kind: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners IX, LP ("NVP IX") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP IX, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F1 · price: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners IX, LP ("NVP IX") to its limited and general partners. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP IX, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP IX. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. F2 · balance_after: The NVP IX distribution resulted in a change in the form of beneficial ownership so that following the distribution (i) 68,317 shares were beneficially owned by the Howard 2001 Revocable Trust, of which Mr. Howard is a trustee, and (ii) 34,148 shares were beneficially owned by the Crowe Family Trust, 12/22/88, of which Mr. Crowe is a trustee. F2 · ownership.nature: The NVP IX distribution resulted in a change in the form of beneficial ownership so that following the distribution (i) 68,317 shares were beneficially owned by the Howard 2001 Revocable Trust, of which Mr. Howard is a trustee, and (ii) 34,148 shares were beneficially owned by the Crowe Family Trust, 12/22/88, of which Mr. Crowe is a trustee. Read SEC document |
| October 25, 2015 Filed Oct 27, 2016 18:47 UTC | Apigee Corp APIC · Entity 181062 | OtherCommon Stock | 472,557 | $0.00 | $0.00 |
DisclosureSEC source: 0001209191-16-147200 · doc4.xml · nonDerivative · entry 3 Norwest Venture Partners IX, LP · CIK 0001309124 · 10% owner Crowe Jeffrey · CIK 0001535261 · 10% owner Howard Matthew D. · CIK 0001576176 · 10% owner NORWEST VENTURE PARTNERS VIII LP · CIK 0001176230 · 10% owner Norwest Venture Partners XI, LP · CIK 0001534522 · 10% owner Joint disclosure: these amounts are not allocated separately to each reporting owner. 10b5-1 filing: Not disclosed Ownership: Indirect · By Limited Partnership Disclosed balance after: 0 F5 · kind: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited and general partners. F5 · price: Shares were disposed via a pro rata in-kind distribution of Issuer's stock from Norwest Venture Partners XI, LP ("NVP XI") to its limited and general partners. F6 · ownership.nature: The securities shown on Line 3 of Table 1 represent securities held of record by NVP XI. By virtue of their position as co-Chief Executive Officers of NVP Associates, LLC ("NVP Associates"), the managing member of the general partner of NVP XI, Jeffrey Crowe and Matthew D. Howard may be deemed to share voting and dispositive power over the shares held by NVP VIII. Messers. Crowe and Howard disclaim beneficial ownership of all such securities, except to the extent of any pecuniary interest therein. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.